Navigating the pharmacotherapeutic management of comorbid inflammatory bowel disease and primary sclerosing cholangitis
Brigid Pinnuck(Royal Adelaide Hospital), Kate D. Lynch(Royal Adelaide Hospital)
Cited by 6
Related Papers
Obeticholic acid—a new therapy in PBC and NASH
|British Medical Bulletin|2020|123
Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System
|Hepatology|2018|106
Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases
|Clinical Gastroenterology and Hepatology|2019|104
Lymphocyte Activation Gene (LAG)-3 Is Associated With Mucosal Inflammation and Disease Activity in Ulcerative Colitis
|Journal of Crohn s and Colitis|2020|55
Effects of Tumor Necrosis Factor Antagonists in Patients With Primary Sclerosing Cholangitis
|Clinical Gastroenterology and Hepatology|2020|51